JP7558187B2 - 貧血の処置におけるムスカリン性アセチルコリン受容体サブタイプ４アンタゴニスト - Google Patents

貧血の処置におけるムスカリン性アセチルコリン受容体サブタイプ４アンタゴニスト Download PDF

Info

Publication number
JP7558187B2
JP7558187B2 JP2021553300A JP2021553300A JP7558187B2 JP 7558187 B2 JP7558187 B2 JP 7558187B2 JP 2021553300 A JP2021553300 A JP 2021553300A JP 2021553300 A JP2021553300 A JP 2021553300A JP 7558187 B2 JP7558187 B2 JP 7558187B2
Authority
JP
Japan
Prior art keywords
formula
compound
bfu
ethyl
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021553300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525293A (ja
JP2022525293A5 (cg-RX-API-DMAC7.html
Inventor
アベド， ユーセフ アル
リンボ ジャン，
Original Assignee
コールド スプリング ハーバー ラボラトリー
ザ ファインスタイン インスティチューツ フォー メディカル リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コールド スプリング ハーバー ラボラトリー, ザ ファインスタイン インスティチューツ フォー メディカル リサーチ filed Critical コールド スプリング ハーバー ラボラトリー
Publication of JP2022525293A publication Critical patent/JP2022525293A/ja
Publication of JP2022525293A5 publication Critical patent/JP2022525293A5/ja
Priority to JP2024081788A priority Critical patent/JP2024102364A/ja
Application granted granted Critical
Publication of JP7558187B2 publication Critical patent/JP7558187B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021553300A 2019-03-25 2020-03-20 貧血の処置におけるムスカリン性アセチルコリン受容体サブタイプ４アンタゴニスト Active JP7558187B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024081788A JP2024102364A (ja) 2019-03-25 2024-05-20 貧血の処置におけるムスカリン性アセチルコリン受容体サブタイプ４アンタゴニスト

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962823214P 2019-03-25 2019-03-25
US62/823,214 2019-03-25
PCT/US2020/023989 WO2020198054A1 (en) 2019-03-25 2020-03-20 Muscarinic acetylcholine receptor subtype 4 antagonists in the treatment of anemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024081788A Division JP2024102364A (ja) 2019-03-25 2024-05-20 貧血の処置におけるムスカリン性アセチルコリン受容体サブタイプ４アンタゴニスト

Publications (3)

Publication Number Publication Date
JP2022525293A JP2022525293A (ja) 2022-05-12
JP2022525293A5 JP2022525293A5 (cg-RX-API-DMAC7.html) 2023-03-28
JP7558187B2 true JP7558187B2 (ja) 2024-09-30

Family

ID=72608578

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021553300A Active JP7558187B2 (ja) 2019-03-25 2020-03-20 貧血の処置におけるムスカリン性アセチルコリン受容体サブタイプ４アンタゴニスト
JP2024081788A Pending JP2024102364A (ja) 2019-03-25 2024-05-20 貧血の処置におけるムスカリン性アセチルコリン受容体サブタイプ４アンタゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024081788A Pending JP2024102364A (ja) 2019-03-25 2024-05-20 貧血の処置におけるムスカリン性アセチルコリン受容体サブタイプ４アンタゴニスト

Country Status (12)

Country Link
US (1) US12497411B2 (cg-RX-API-DMAC7.html)
EP (1) EP3946321A4 (cg-RX-API-DMAC7.html)
JP (2) JP7558187B2 (cg-RX-API-DMAC7.html)
KR (1) KR102914803B1 (cg-RX-API-DMAC7.html)
CN (1) CN113613650B (cg-RX-API-DMAC7.html)
AU (1) AU2020247812B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021019189A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132381A1 (cg-RX-API-DMAC7.html)
IL (1) IL286617A (cg-RX-API-DMAC7.html)
MX (1) MX2021011588A (cg-RX-API-DMAC7.html)
SG (1) SG11202109857UA (cg-RX-API-DMAC7.html)
WO (1) WO2020198054A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113613650B (zh) 2019-03-25 2024-12-10 冷泉港实验室 治疗贫血的毒蕈碱乙酰胆碱受体亚型4拮抗剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002114786A (ja) 2000-09-22 2002-04-16 Warner Lambert Co Ｍ４選択性アザアントラセンムスカリンレセプター拮抗薬としてインドールを含む縮合環系
WO2018022668A2 (en) 2016-07-26 2018-02-01 Flagship Pioneering, Inc. Neuromodulating compositions and related therapeutic methods for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3649626A (en) * 1970-04-27 1972-03-14 Warner Lambert Co Fused ring systems containing (1 3)oxazine
DK1282625T3 (da) * 2000-05-09 2004-11-15 Warner Lambert Co Anvendelsen af benzoxaziner i behandlingen af Parkinsons sygdom
US8329689B2 (en) * 2006-05-23 2012-12-11 Alexandre Vasilievich Ivachtchenko Substituted indoles and a method for the production and use thereof
US20130059783A1 (en) * 2010-03-12 2013-03-07 Johan Flygare Compositions and methods for expanding bfu-e cells
WO2019010491A1 (en) * 2017-07-07 2019-01-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS
CN113613650B (zh) 2019-03-25 2024-12-10 冷泉港实验室 治疗贫血的毒蕈碱乙酰胆碱受体亚型4拮抗剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002114786A (ja) 2000-09-22 2002-04-16 Warner Lambert Co Ｍ４選択性アザアントラセンムスカリンレセプター拮抗薬としてインドールを含む縮合環系
WO2018022668A2 (en) 2016-07-26 2018-02-01 Flagship Pioneering, Inc. Neuromodulating compositions and related therapeutic methods for the treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters，1998年，8，1991-1996

Also Published As

Publication number Publication date
SG11202109857UA (en) 2021-10-28
IL286617A (en) 2021-10-31
KR102914803B1 (ko) 2026-01-20
CA3132381A1 (en) 2020-10-01
EP3946321A4 (en) 2023-03-08
JP2024102364A (ja) 2024-07-30
JP2022525293A (ja) 2022-05-12
MX2021011588A (es) 2021-12-15
CN113613650B (zh) 2024-12-10
AU2020247812B2 (en) 2025-09-11
BR112021019189A2 (pt) 2021-11-30
KR20210144697A (ko) 2021-11-30
AU2020247812A1 (en) 2021-09-30
US20220185821A1 (en) 2022-06-16
CN113613650A (zh) 2021-11-05
WO2020198054A1 (en) 2020-10-01
EP3946321A1 (en) 2022-02-09
US12497411B2 (en) 2025-12-16

Similar Documents

Publication Publication Date Title
JP6970802B2 (ja) 二官能性分子によって標的化タンパク質分解を誘導する方法
CA3039760C (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
KR102241258B1 (ko) 암을 치료하기 위한 1-테트라히드로피라닐카르보닐-2,3-디히드로-1h-인돌 화합물
KR20230058614A (ko) 암 치료를 위한 kat6 억제제 방법 및 조합
JP2020059748A (ja) ラミノパシー、老化及び癌を治療又は予防するためのｎａｔ１０モジュレーター
TW201542549A (zh) 新穎雜環化合物
EP3108883A1 (en) Therapeutic uses of non-peptide inhibitors of the calcineurin - nfat signalling pathway
JP2011526295A (ja) ５員および６員複素環化合物
WO2020257184A1 (en) Methods for modulating splicing
WO2020076738A2 (en) Protein-binding compounds
JP2022522942A (ja) 有機化合物
CA3238771A1 (en) Hetero-atom containing compounds and uses thereof
KR20210031717A (ko) 피롤로[1,2-b]피리다진 유도체
EP4227306A1 (en) Heterocyclic substituted fused gamma-carboline derivative, preparation method therefor, intermediate thereof and use thereof
JP2024102364A (ja) 貧血の処置におけるムスカリン性アセチルコリン受容体サブタイプ４アンタゴニスト
EP2890382B1 (en) Compositions and methods for inhibiting activity of hypoxia-inducible transcription factor complex and its use for treatment of tumors
EP4460492A1 (en) Compounds containing a hydroxyphenyl moiety and their use
CN117916234A (zh) 作为tyk2/jak1假激酶结构域抑制剂的化合物及合成和使用方法
KR20220114569A (ko) 항암 화합물로서 cullin 3 어댑터 kbtbd4의 모듈레이터
US20240391880A1 (en) KCa3.1 INHIBITORS FOR PODOCYTE PROTECTION
WO2021003339A1 (en) Amp-activated protein kinase inhibitors and methods of making and using the same
US20230145868A1 (en) Urea inhibitors of micro-rna
JP2025521593A (ja) ３βＨＳＤ１阻害剤及び組成物ならびにそれらの使用
EP4688148A1 (en) Selective rapamycin analogs and uses thereof
WO2024159067A1 (en) Compounds and methods for yap/tead modulation and indications therefor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230317

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240520

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240820

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240917

R150 Certificate of patent or registration of utility model

Ref document number: 7558187

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150